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The treatment of tuberculosis (TB) in children and adults has 
remained unchanged for more than 30 years, and although 
new drugs are at last entering clinical trials it will be  5 - 10 
years before their precise place in therapy is established. It is 
therefore necessary to continue to use our current drugs with 
care and prudence and be particularly careful about preventing 
the further development of drug resistance. The principles of 
treatment in adults and children are the same, but there is an 
increasing appreciation that the spectrum of disease seen in 
childhood is different and that children also differ from adults 
with regard to the pharmacokinetics of drugs.
Drugs differ in their action on different 
populations of mycobacteria 
Several populations of mycobacteria can be identified within 
TB lesions.1 Within the walls of cavities there is a large 
population of actively multiplying organisms. A typical cavity 
might contain 108 bacilli, and this large population increases 
the probability that mutations will occur that select for drug 
resistance. Smaller populations of progressively less active 
or dormant organisms will be found in caseation tissue and 
within macrophages. Killing the metabolically active organisms 
is a relatively easy task, and isoniazid (INH) is responsible 
for the death of 90% of these bacilli within 48 hours. The 
elimination of the intermittently active or dormant organisms 
is more difficult and it is failure to sterilise lesions by killing 
these persistent bacilli that leads to relapse. Drugs that rapidly 
eliminate the great bulk of metabolically active bacilli are 
termed bactericidal drugs, and the most active bactericidal 
agent is INH, with rifampicin (RMP) being about half as active 
in this respect.2 Drugs that eliminate persisting intermittently 
active or dormant bacilli are termed sterilising agents, the most 
important being RMP and pyrazinamide (PZA); without them 
6-month short-course treatment is not possible. INH will also 
ultimately sterilise lesions but this requires at least a year of 
treatment. 
Essential anti-TB agents
Five drugs, INH, RMP, PZA, ethambutol (EMB) and 
streptomycin (SM), are regarded as essential agents by the 
World Health Organization (WHO).3 RMP, INH and PZA are 
the most important elements in our current ‘first-line’ regimen. 
For most forms of uncomplicated childhood TB these three 
drugs are adequate. PZA completes most of its activity within 
the first 2 months of treatment; it is therefore customary to talk 
of an ‘intensive’ phase of treatment with INH, RMP and PZA, 
the main focus being to eliminate the bulk of the bacilli, and 
a 4-month ‘sterilising’ or ‘continuation’ phase with INH and 
RMP, when the main focus is the elimination of all remaining 
viable bacilli. When cavitation is present or in the case of more 
serious forms of disease a fourth drug is advisable, usually 
EMB or SM. The purpose of the fourth drug  is to prevent the 
development of drug resistance in the face of a much larger 
bacterial load and prevent the further broadening of the 
resistance spectrum should initial INH resistance be present. 
Neither EMB nor SM has much sterilising activity and although 
EMB is moderately bactericidal at higher doses, SM has very 
low bactericidal activity, as do the other aminoglycosides, 
kanamycin (KM) and amikacin (AMK). The ability to prevent 
resistance in companion drugs is also important, and agents 
that are highly bactericidal will usually be best able to prevent 
resistance in other drugs.
Reserve anti-TB agents 
In addition to the five ‘first-line’ drugs mentioned above 
there are a number of other less effective and often more 
toxic drugs classified by the WHO as reserve agents for use 
in drug resistance or in the event of toxicity or intolerance to 
the first-line agents. These agents include ethionamide (ETH) 
or prothionamide, KM or AMK, terizidone/cycloserine (CS), 
capreomycin (CP), viomycin (VM) and para-aminosalicylic 
acid (PAS). Although they have never been formally evaluated 
as anti-TB agents, the fluoroquinolones now have a well-
established role in the management of drug-resistant TB. 
There is also considerable interest in the possibility that some 
of the more recently developed agents such as gatifloxacin or 
moxifloxacin may contribute to reducing duration of treatment; 
several studies are under way to evaluate this possibility.4 Of 
the two fluoroquinolones available in South Africa at present, 
ofloxacin is to be preferred to ciprofloxacin. 
Multidrug resistance (MDR) in 
children 
MDR in children is fully dealt with in an accompanying paper 
by Schaaf.5 
Response to TB treatment in children
One of the main differences between adult and childhood TB 
is the treatment response. In adult TB this can be measured 
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microbiologically in nearly all cases and relatively little value is 
accorded to clinical or radiological changes. In much childhood 
TB we lack such a ‘gold standard’, but rely on clinical response, 
weight gain and improvement in radiological features. 
However radiology can be misleading and some changes, 
especially mediastinal lymph node enlargement, persist for 
more than a year after successful treatment completion.6,7 
Persistence of changes does not mean that treatment must be 
prolonged if there has been improvement in symptoms and 
weight gain. 
Influence of HIV/AIDS on TB 
treatment in children 
As with other aspects of TB, HIV has complicated childhood 
TB treatment considerably. There is some anecdotal evidence 
that HIV-infected TB patients may benefit from an extension of 
TB treatment from 6 to 9 months.8,9 Very few data are available 
with regard to this aspect of TB treatment in children, but in 
more serious forms of disease it would be prudent to continue 
INH and RMP until 9 months in HIV-infected children. It 
must also be kept in mind in planning antiretroviral treatment 
that RMP has important interactions with some antiretroviral 
agents. This is particularly true of the non-nucleoside reverse 
transcriptase inhibitors. If in doubt in this regard, seek advice 
from those who regularly manage TB in HIV-infected children.   
Pharmacokinetics of anti-TB agents in 
children 
In calculating the dosage of drugs for children it is recognised 
that body surface area provides a more accurate measure 
of appropriate dose than mg/kg body weight; nonetheless 
dosages currently recommended by the WHO for TB 
treatment are the same in adults and children. Several recent 
studies show that children receiving the same mg/kg body 
weight doses of anti-TB agents as adults have lower serum 
concentrations than adults.10,11 Until this position is resolved it 
would be wise to calculate dosages for children making use of 
the upper limits of the suggested ranges. 
The dosages recommended by the WHO for the treatment 
of TB in children and their commonest side-effects are 
summarised in Table I and the recommended regimens for 
the different categories of TB in Table II.3,12 Whenever possible 
children should be included in one of these categories to 
ensure the full integration of childhood TB into national 
programmes. Most children will be sputum or gastric aspirate 
smear-negative and thus be included in category III. Children 
presenting in category III with limited lung opacification and 
non-cavitating disease, without any other complicating factor 
such as HIV infection, can be treated without EMB. In the case 
of TB meningitis it is recommended that SM replace EMB, 
but neither drug has very good entry into the cerebrospinal 
fluid. In South Africa a regimen of INH, RMP, PZA and ETH, 
all given for 6 months, has been used with success and a low 
relapse rate in the management of TB meningitis in children.13 
INH may cause symptomatic pyridoxine deficiency, so it 
is recommended that children who are malnourished, HIV-
infected children, breastfeeding infants or pregnant adolescents 
should receive supplemental pyridoxine 5 - 10 mg/kg/d.12
Directly observed therapy, short course 
(DOTS)
It is the bitter experience of TB services worldwide that a 
significant proportion of patients fail to comply with treatment 
recommendations. In the case of children a further element is 
introduced as young children are dependent on their parents 
or caregivers for their treatment. As support for patients to 
encourage completion of treatment as prescribed, the WHO 
now advocates DOTS. This approach emphasises standardised 
short-course chemotherapy under proper case management 
conditions, including direct observation of treatment. This 
Table I. World Health Organization recommended dosages and side-effects of essential antituberculosis agents3,12
          Dose in mg/kg (range)  
Drug  Daily               Thrice weekly  Commonest side-effects
Isoniazid  5 (4 - 6)                 10 (8 - 12)   Hepatotoxicity, peripheral neuropathy, less commonly optic   
  Maximum    neuritis or psychosis, concentrations of carbamazepine and  
  300 mg     phenytoin may increase
Rifampicin 10 (8 - 12)                 10 (8 - 12)   Hepatotoxicity, exfoliative dermatitis in HIV-infected patients. With  
  Maximum    intermittent use flu syndrome and thrombocytopenia may occur.  
  600 mg     Induction of enzymes increases dosage requirements for  
        corticosteroids, oral hypoglycaemic agents, digitalis and other  
       agents
Pyrazinamide 25 (20 - 30) 35 (30 - 40)  Hepatotoxicity, hyperuricaemia with arthralgia and arthritis,  
       particularly of shoulders, hypersensitivity reactions, especially  
       flushing of the skin
Ethambutol 20 (15 - 25) 30 (25 - 35)  Dose-dependent optic neuritis with impairment of visual acuity  
       and colour vision. Rare in children at recommended doses
Streptomycin 15 (12 - 18) 15 (12 - 18)  Irreversible auditory nerve damage, hypersensitivity reactions
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implies technically sound and socially supportive treatment 
services. While the principles underlying DOTS are clear, 
their application to children is uncertain, and it has not been 
established how far a family-orientated approach to TB 
treatment of children can be adopted, and whether parents or 
other family members can be reliable treatment supervisors. 
The application of DOTS to childhood TB requires further 
study. 
Future developments 
The HIV/AIDS pandemic has focused attention on the serious 
nature of the ongoing TB epidemic in developing countries, 
and the devastating interaction of HIV and TB has dispelled 
any illusions that TB is under control. Explosive epidemics of 
drug resistance have exposed the limits of the anti-TB drug 
armamentarium. There is now an awareness of the urgent need 
for new anti-TB agents. In 2000 the Global Alliance for TB Drug 
Development was established to accelerate the development 
of new anti-TB agents.14 For the first time in decades there 
is a promising pipeline of more than 20 compounds in 
development under the guidance of the Global Alliance or 
pharmaceutical companies. Several drugs with very promising 
characteristics during in vitro and in vivo animal studies15,16 
have already completed preliminary studies. However, before 
they can be used in routine regimens, a considerable amount 
of work must still be done; at any stage problems may be 
encountered precluding further development. Therefore, 
despite a more optimistic outlook than has been justified for 
several decades, it behoves all concerned about TB control and 
treatment to use existing regimens and drugs with due care 
and to do everything possible to prevent the development of 
drug resistance. 
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Table II. Regimens recommended by the World Health Organization for management of tuberculosis3,12
               TB treatment regimens
       Intensive initial phase  Continuation phase   
Diagnostic category  TB patient   (daily or thrice weekly) (daily or thrice weekly)
I   New smear-positive patients;  2HRZE   4HR or 6HE daily   
   new smear-negative PTB with         
   extensive lung involvement; severe         
   concomitant HIV disease or severe         
   extrapulmonary TB
II   Previously treated smear-positive  2HRZES/1HRZE  5HRE    
   PTB following relapse,          
   treatment after interruption or         
   treatment failure
III   New smear-negative PTB   2HRZE   4HR or 6HE daily   
   (other than category I); less severe         
   forms of extrapulmonary TB
IV   Chronic and MDR TB  Specialised treatment needed under the guidance of a   
       specialist
H = isoniazid; R = rifampicin; Z = pyrazinamide; E = ethambutol; S = streptomycin. The numerical prefix refers to the length of time in months. TB = tuberculosis; PTB = pulmonary 
tuberculosis; MDR = multidrug-resistant.
Pg 992-994.indd   994 9/18/07   11:36:50 AM
